Testosterone Replacement Therapy
Areas we serve in ME and NH
GLP-1 Weight Loss
Hormone Replacement Therapy
Functional Medicine
Services & Treatments
Conditions We Treat
INSIGHTS
Functional medicine insights, treatment guides, and health education from the Med Matrix team.
We rebuilt medmatrixusa.com from scratch. New service pages, real patient stories, provider bios, podcast episodes, and a faster, easier experience on every device.
FDA scientists recommended against making seven peptides easier to compound, and an advisory committee votes July 23-24, 2026. What the review covers, why it is not a ban, and what it means if peptides are part of your plan.
You cleaned up your diet but the scale barely moved. A 2026 WHO study of 15,200 people found ultra-processed food leaves a measurable fingerprint in your blood. What those markers mean, and why the scale is the wrong scoreboard for how food is treating you.
The FDA's proposal to end large-scale compounding of semaglutide has a new comment deadline: July 30, 2026. The direction has not changed. What the docket means if you're on a compounded GLP-1, and how to plan a transition before the rule is final.
A 13,000-patient cohort presented at Heart Rhythm 2026 found GLP-1 medications tied to lower atrial fibrillation risk, even in patients who gained weight. What the finding means, what it does not, and who should keep an eye on heart rhythm during treatment.
For decades, chronic fatigue could only be diagnosed by ruling everything else out. New research on a blood test with 96 percent accuracy is changing that, and it validates every patient who was told their labs look normal.
Testosterone therapy works on a schedule. Libido and energy move first, strength follows, and body composition takes about three months. A 2026 study of 9,537 men mapped the timeline, and follow-up labs at each checkpoint tell you whether your protocol is on track.
Your TSH came back normal, but you're still exhausted, gaining weight, and cold in July. One test can't see a conversion problem, a reverse T3 block, or early Hashimoto's antibodies. The full six-marker panel to ask for, by name.
Cheap semaglutide ads are everywhere, and the FDA keeps sending warning letters to the companies behind them. What the letters say, the red flags to check before buying a GLP-1 online, and how a supervised local program differs.
Medicare now covers certain GLP-1 weight loss medications for a flat $50 monthly copay. Who qualifies, which formulations made the list, the fine print about deductibles and end dates, and the unpublicized pricing condition behind the deal.
The scale stopped moving even though nothing changed. A plateau on a GLP-1 is normal, but it's usually a signal. Here's what a real workup checks: dose, lifestyle, and the biology most programs never test.
Wegovy and Ozempic are both semaglutide. Zepbound and Mounjaro are both tirzepatide. What actually separates the four brand names, what the SURMOUNT-5 head-to-head trial found, and why the program around the prescription matters more than the name on the pen.
Alli has been on pharmacy shelves since 2007. In June 2026 the FDA added a warning for acute kidney injury and kidney stones. What the label change says, who should pay attention, and why supervised weight loss looks different.
